Biotechnologies Novome is a San Francisco-based biotechnology company focused on engineering the definition of the human gut microbiome to treat chronic diseases. Novome Biotechnologies has developed the first platform to control intestinal colonization with engineered microorganisms: Genetically Engineered Microbial Medicines (GEMMs). The Novome Biotechnologies platform is based on Stanford’s pioneering technology to implant GEMMs in the gut, enabling sustained and effective treatment. Recently, Novome Biotechnologies received US$43.5 million in Series B financing, led by Tencent Investment, with participation from Alexandria Venture Investments, Alta Partners, 5AM Ventures, DCVC Bio, Touchdown Ventures, Colorcon Ventures, Navian Investments, and University of Minnesota.
This article is reproduced from: https://www.itjuzi.com/investevent/13547280
This site is for inclusion only, and the copyright belongs to the original author.